Moderna Files COVID-19 Vaccine After Second Impressive Read-Out
Does It Have Edge In Preventing Severe Cases?
Executive Summary
Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.
You may also be interested in...
Quick Listen: Scrip’s Five Must-Know Things
Join us for a brief audio tour around the past week's major biopharma industry developments, as reported by Scrip's global team.
Coronavirus Update: After UK Nod, New Forecast Makes Pfizer Vaccine The Leader
After its historic first emergency approval, analysts at Bernstein has upgraded predictions for Pfizer/BioNTech's COVID-19 vaccine in 2021 and beyond.
Precious Cargo: DHL Gears To Deliver COVID-19 Vaccines
A senior executive shares insights around how the global logistics provider is preparing to deliver the upcoming COVID-19 vaccines across the world. While the company has prior experience with the "deep frozen" temperatures needed for some candidates, there will still be specific challenges and complexities involved.